BioMerieux SA

BIM: XPAR (FRA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
#T>LOCK|%S<FLOCK|<Z?w%#

BioMérieux's Strong Product Placements Support Long-Term Growth; Shares Remain Undervalued

Business Strategy and Outlook

BioMérieux is a specialist in the fragmented in vitro diagnostics market, with expertise in microbiology testing and syndromic molecular testing. The company is also active in the immunoassays market.

Sponsor Center